Date Published: May 24, 2009
Publisher: Wiley Subscription Services, Inc., A Wiley Company
Author(s): Alzbeta Vazna, Clare Beesley, Linda Berna, Larisa Stolnaja, Helena Myskova, Michaela Bouckova, Hana Vlaskova, Helena Poupetova, Jiri Zeman, Martin Magner, Anna Hlavata, Bryan Winchester, Martin Hrebicek, Lenka Dvorakova.
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder that is caused by a deficiency of the enzyme α-l-iduronidase (IDUA). Of the 21 Czech and Slovak patients who have been diagnosed with MPS I in the last 30 years, 16 have a severe clinical presentation (Hurler syndrome), 2 less severe manifestations (Scheie syndrome), and 3 an intermediate severity (Hurler/Scheie phenotype). Mutation analysis was performed in 20 MPS I patients and 39 mutant alleles were identified. There was a high prevalence of the null mutations p.W402X (12 alleles) and p.Q70X (7 alleles) in this cohort. Four of the 13 different mutations were novel: p.V620F (3 alleles), p.W626X (1 allele), c.1727 + 2T > G (1 allele) and c.1918_1927del (2 alleles). The pathogenicity of the novel mutations was verified by transient expression studies in Chinese hamster ovary cells. Seven haplotypes were observed in the patient alleles using 13 intragenic polymorphisms. One of the two haplotypes associated with the mutation p.Q70X was not found in any of the controls. Haplotype analysis showed, that mutations p.Q70X, p.V620F, and p.D315Y probably have more than one ancestor. Missense mutations localized predominantly in the hydrophobic core of the enzyme are associated with the severe phenotype, whereas missense mutations localized to the surface of the enzyme are usually associated with the attenuated phenotypes. Mutations in the 130 C-terminal amino acids lead to clinical manifestations, which indicates a functional importance of the C-terminus of the IDUA protein. © 2009 Wiley-Liss, Inc.
Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder which is caused by a deficiency of the enzyme α-l-iduronidase (IDUA, EC 18.104.22.168; OMIM *252800). This leads to widespread accumulation of the sulfated glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate inside lysosomes [Hopwood and Morris, 1990; Neufeld and Muenzer, 2001].